Advanced searches left 3/3

Cyclophosphamide - Europe PMC

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

Potential applications of PEGylated green gold nanoparticles in cyclophosphamide-induced cystitis.

Cyclophosphamide -induced cystitis was discovered by green tea extract PEGylated gold nanoparticles, whose aim and sustained drug delivery was investigated. Following the concept of green synthesis, AuNPs were synthesized by reduction of gold salts' reaction with green tea extract. P-AuNPs pre-treatment before the CYP challenge showed its uroprotective abilities. P-AuNP-induced bladder tissue damage discovered by macroscopic and histological studies was dramatically reduced by P-AuNPs, as well as reduced fibrosis of collagen fibre in bladder smooth muscles revealed by Masson's trichrome staining.

Source link: https://europepmc.org/article/MED/35620802


Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.

In transplant-eligible transplanted multiple myeloma patients in Japan, we conducted a phase II trial to objectively evaluate the effectiveness and safety of bortezomib-cyclophosphamide-dexamethasone induction, autologous stem cell transplantation, VCD reconstruction, and bortezomib maintenance. Describes Patients In 15 centers from 2013 to 2016, 42 patients with a median age of 58 years were admitted to NDMM in 2013. Following the treatment and sCR/sCR and VGPR rate 100 days after ASCT was 26% and 17%, respectively, twenty-six of the 42 patients completed ASCT. Eight of the 18 patients completed 2-year bortezomib therapy with no disease progression or grade 3/4 toxicities. After ASCT, five patients were VGPR or partial response, but the clinic stayed open with 2-year bortezomib maintenance. Conclusion In Japan, VCD's induction/consolidation/bortezomib care with ASCT resulted in a high CR/sCR ratio and extended progressive life.

Source link: https://europepmc.org/article/MED/35152852


Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.

It's unknown what the ideal conditioning regimen for haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute myeloid leukemia. On the other hand, a reduced intensity conditioning program consisting of thiotepa and reduced-dose busulfan with fludarabine may reduce AML relapse. In two separate populations based on age, we retrospectively compared CyFluTBI versus TBF in CR AML patients who underwent Haplo-SCT with PT-Cy. Younger patients are likely to benefit from conditioning intensification from CyFluTBI to TBF regimens prior to PT-Cy Haplo-SCT for CR AML, while older ones do not.

Source link: https://europepmc.org/article/MED/35752739


Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.

Bortezomib, a proteasome inhibitor that has been used in combination with cyclophosphamide and dexamethasone, has demonstrated efficacy in the treatment of newly diagnosed and relapsed AL amyloidosis in patients. Ixazomib is the first oral PI to be approved in routine usage, but it has not been tested in the upfront treatment setting yet. Patients with measurable disease and good organ function were recruited into an AL amyloidosis patient with measurable disease and stable organ function. With cyclophosphamide and dexamethasone, the primary aim was to determine the hematologic response rate of ixazomib in combination with cyclophosphamide and dexamethasone. Induction was 63% and included complete response in 11. 4% and a stifled reaction in 37 percent of patients, with excellent partial response in 37. 9%. The 2-year PFS and OS were 74% and 88%, respectively, with a median follow-up of 29. 7 months for the living patients. 7. 5 months was the average time to switch therapy. In 23% and 49% of patients, respectively, Grade u22653 hematological and non-hematologic adverse events occurred in 23% and 49%.

Source link: https://europepmc.org/article/MED/35737873


Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

In newly diagnosed multiple myeloma and relapsed multiple myeloma, daratumab + cyclophosphamide/bortezomib/bortezoma was safe and well tolerated in the primary analysis of LYRA. The final report of LYRA indicates that after all patients completed study therapy and were followed for 36 months or discontinued, we published the final report. The four-month progression-free survival rates were 48. 7% and 29. 8% for NDMM transplant and non-transplant recipients, respectively, with 48. 7% and 29. 8% for NDMM transplant and non-transplant patients, respectively.

Source link: https://europepmc.org/article/MED/35730586


Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.

We created CN06 as a dual activator of the constitutive androstane receptor and nuclear factor erythroid 2-related factor 2 in a two-factory manner similar to factor 2 in a high-throughput screening and chemical synthesis approach. We show that CN06 caused CPA/DoX-mediated TNBC cell death via CAR-dependent CYP2B6 induction and subsequent conversion of CPA to its active metabolite 4-hydroxy-CPA, while shielding against DOX-induced cardiotoxicity by selectively activating Nrf2-antioxidant signaling in cardiomyocytes but not in TNBC cells.

Source link: https://europepmc.org/article/MED/35579950


Rapamycin maintains the primordial follicle pool and protects ovarian reserve against cyclophosphamide-induced damage.

Any abnormal onset of primordial follicles and subsequent depletion will irreversibly reduce the ovarian reserve, which is one of the most common chemotherapy-induced adverse effects in young patients with cancer. In subsequent experiments, a daily intake of 5 mg/kg rapamycin in 50 SPF female C57BL/6 mice was determined as the appropriate dose and duration for administration. Co-administration of rapamycin reduced primordial follicle loss and the formation of follicular cell apoptosis, thereby rescuing the ovarian reserve following CTX therapy. We found that rapamycin significantly reduced CTX-mediated overactivation of mTOR and its downstream molecules on mTOR's signaling pathway. These results indicate that rapamycin has the ability to maintain the ovarian primordial follicle pool and maintain fertility in young female patients with cancer chemotherapy.

Source link: https://europepmc.org/article/MED/35718464


Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis.

Abstract: Patients are allergic to high-dose GC monotherapy, but it is the first choice for dermatomyositis complicated by interstitial lung disease. Patients in the CT cohort had CY in significantly smaller amounts than those in the TI cohort during treatment, indicating significantly less than those in the TI cohort during therapy. A total of 11 patients from the TI cohort and 14 patients from the CT cohort were hospitalized, while 14 patients from the CT cohort were also relapsed. Patients of the TI cohort had an event-free survival at the end of the 30-months, more than those of the CT cohort. Also, higher numbers of patients of the TI cohort survived after an event than those of the CT cohort. Patients of the CT cohort of the CT cohort suffered from renal disease. CY's addition of TAC to high doses GC with CY is an effective treatment for DM-ILD-related DM-ilD related disorders.

Source link: https://europepmc.org/article/MED/35713427


Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT.

Background: For acute myeloid leukemia, the use of haploidentical cell transplantation with peripheral blood stem cells is on the rise. In Haplo-PBSC, we investigated whether adding antithymocyte globulin to post-transplant cyclophosphamide results in better outcomes than PTCy alone. In comparison to cyclosporine A and mycophenolate mofetil as other immunosuppressive agents, we found 441 adult patients undergoing a first or second complete remission in AML in first or second complete remission; graft-versus-host disease prophylaxis included either PTCy alone or ATG+PTCy. No statistical differences in transplant outcomes were found between PTCy and ATG+PTCy in univariate analysis. ATG+PTCy's multivariate analysis revealed a reduced risk of chronic GVHD in comparison to PTCy alone. Conclusions In Haplo-PBSC, the addition of ATG to PTCy is a good idea, it's also less effective at reducing transplant toxicity, mortality, or relapse rates are comparable to those with PTCy alone, with decreased transplant toxicity, incidence, or relapse rates.

Source link: https://europepmc.org/article/MED/35714906


Development and biological evaluation of protective effect of kidney targeted N-acetylated chitosan nanoparticles containing thymoquinone for the treatment of DNA damage in cyclophosphamide-induced haemorrhagic cystitis.

The most important component of Nigella sativa seeds, Thymoquinone, is reported to have an organ protective role by Nrf2 expression and the production of Phase-II antioxidant enzymes. The sudden onset of haematuria, bladder pain, and irritable bladder symptoms are all typical side effects of cyclophosphamide chemotherapy. CYP-induced haemorrhagic cystitis is the product of this study's aim. TQ-NP prepared by ionic gelation technique provides kidney targeted delivery of TQ as opposed to the TQ solution, according to the TQ solution. In addition, TQ-NP administrations provided more safeguard against the normal histological changes in the bladder in comparison to TQ's TQ-NP approach. TQ-NP exhibits potent anti-oxidant, DNA protect, and cytokine inhibitory activity in much lower amounts relative to simple TQ solutions, according to the present study.

Source link: https://europepmc.org/article/MED/35714868

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions